Tofacitinib Found to Relieve Symptoms of Ulcerative Colitis

Share this content:
Tofacitinib Found to Relieve Symptoms of Ulcerative Colitis
Tofacitinib Found to Relieve Symptoms of Ulcerative Colitis

THURSDAY, May 4, 2017 (HealthDay News) -- Patients with moderate-to-severe ulcerative colitis who haven't done well on other treatments may have success with tofacitinib (Xeljanz), according to a study published in the May 4 issue of the New England Journal of Medicine.

The researchers randomly assigned 1,732 patients with ulcerative colitis to one of three phase 3 trials. The first two trials looked at 1,139 patients with moderate-to-severe ulcerative colitis who had failed with conventional treatment or treatment with a tumor necrosis factor antagonist such as infliximab. They received tofacitinib or a placebo twice a day for eight weeks. In the third trial, 593 patients who responded to tofacitinib were assigned to a maintenance dose (one group with 5 mg and another group with 10 mg) of the drug, or placebo for a year.

In the first trial, 18.5 percent of the patients taking tofacitinib experienced a remission of their condition in eight weeks. That compared to just 8.2 percent of patients receiving placebo. In the second trial, 16.6 percent of those taking tofacitinib had a remission, compared with 3.6 percent of those taking placebo, the researchers found. In the third trial, 34.3 percent of patients taking 5 mg of tofacitinib had disease remission after one year, while 40.6 percent of those taking a 10-mg dose of the drug had remission at a year. Only 11.1 percent of patients on placebo saw a remission.

"The rate of serious infection was similar across the three treatment groups, and the rates of overall infection and herpes zoster infection were higher with tofacitinib than with placebo," the authors write. "Across all three trials, adjudicated nonmelanoma skin cancer occurred in five patients who received tofacitinib and in one who received placebo, and adjudicated cardiovascular events occurred in five who received tofacitinib and in none who received placebo; as compared with placebo, tofacitinib was associated with increased lipid levels."

The study was funded by Pfizer, the manufacturer of tofacitinib. One author disclosed receiving research grants from and serving as a consultant for Pfizer.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Cost-Effectiveness of PCSK9 Inhibitors Called Into Question

Cost-Effectiveness of PCSK9 Inhibitors Called Into Question

Researchers say price would have to be between $4,000 and $5,000 per year to be cost-effective

Vitamin B6, B12 Supplements May Up Risk of Lung Cancer in Men

Vitamin B6, B12 Supplements May Up Risk of ...

Increased odds only seemed to affect men or male smokers

Tablet Use Encourages Patients to Explore Diabetes Risk

Tablet Use Encourages Patients to Explore Diabetes Risk

Replacing magazines with tablets can help patients learn about diabetes risk, take preventive action

is free, fast, and customized just for you!

Already a member?

Sign In Now »